News
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25 ...
The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...
The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...
13h
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injection"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
3d
InvestorsHub on MSNPositive CHMP Opinion for Gilead’s Lenacapavir in HIV PreventionGilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...
Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025/ PRNewswire/-- Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency ...
CHMP issues negative opinion on conditional marketing authorization for Roche’s gene therapy, Elevidys for Duchenne muscular dystrophy: Basel Monday, July 28, 2025, 15:00 Hrs [I ...
BeiGene's Tevimbra gets a highly sought after recommendation. The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive ...
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 ...
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results